… Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors. A message has been sent to your recipient's email address with a link to the content webpage. Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels. Use immediately (within 1 hour) following reconstitution.

Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk.

A causal relationship between the occurrence of venous thromboembolism and treatment with olanzapine has not been established. If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood symptoms, as clinically indicated.During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 5- 20 mg/day. Lithium: May enhance the neurotoxic effect of Antipsychotic Agents.
Patients with additional risk factors for QTc prolongation may be at even higher risk.QT-prolonging Moderate CYP3A4 Inhibitors (Moderate Risk): May enhance the QTc-prolonging effect of QT-prolonging Antipsychotics (Moderate Risk).

This medicine is available from a pharmacist and requires a prescription. Wait at least 24 hours after the procedure to resume such agents. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. �z����� �S[��)�D�>!Q|�Lt�� ���0( Growth parameters were decreased at high doses.

In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.Olanzapine is not indicated for use in the treatment of children and adolescents. In Section 10 (Date of revision of text), amended to 15 September 2016.

Patients with additional risk factors for QTc prolongation may be at even higher risk.Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.
A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.Olanzapine may antagonise the effects of direct and indirect dopamine agonists.Olanzapine does not inhibit the main CYP450 isoenzymes Olanzapine showed no interaction when co-administered with lithium or biperiden.Therapeutic monitoring of valproate plasma levels did not indicate that valproate dosage adjustment is required after the introduction of concomitant olanzapine.Caution should be exercised in patients who consume alcohol or receive medicinal products that can cause central nervous system depression.The concomitant use of olanzapine with anti-Parkinsonian medicinal products in patients with Parkinson's disease and dementia is not recommended (see section 4.4).Caution should be used if olanzapine is being administered concomitantly with medicinal products known to increase QTc interval (see section 4.4).There are no adequate and well-controlled studies in pregnant women. 0000001727 00000 n 0000094020 00000 n 6.3 Shelf life; 6.4 Special precautions for storage; 6.5 Nature and contents of container; 6.6 Special precautions for disposal and other handling; 7. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.Pimozide: May enhance the QTc-prolonging effect of QT-prolonging Agents (Moderate Risk).Piribedil: Antipsychotic Agents may diminish the therapeutic effect of Piribedil.